Unitree's $53 Billion Close Prices A Humanoid Market Its Own Prospectus Calls Early

Unitree Robotics' shares rose as much as 629% on their Wednesday debut in Shanghai and ended the session up 487%, valuing the company at roughly 358 billion yuan, or about $53 billion ^[1][2]. That number matters beyond Hangzhou because it is the first real public-market pricing of a pure-play humanoid company, and it now becomes the benchmark against which every private round, SPAC and robotics board deck gets compared ^[6].

The operating evidence underneath it is real and modest. Revenue grew more than 300% last year to 1.7 billion yuan, about $252 million ^[3], net profit rose almost 200% to 278.2 million yuan ^[4], and the company is profitable today, which the coverage correctly calls an outlier in the category ^[23]. It shipped more than 5,500 humanoids in 2025 and around 18,000 units across its full range by July 2026 ^[17], at an average humanoid selling price of 166,400 yuan ^[25], roughly $24,700 at the rate implied by its own revenue disclosure ^[26].

Adoption is where the story thins. Unitree's prospectus states the entire humanoid industry is at an early stage of commercialization, that its machines will primarily be used near-term for R&D and stage performances, and that factory work and household chores are the longer-term goal ^[12]. Shen Meng of Chanson & Co told Forbes that a 629% surge was within expectations, and that Unitree's robots are mainly used for research, teaching and performing ^[13]. Unitree did not respond to a request for comment ^[14].

So the price is doing work the deployments are not. At close, the stock traded at almost 1,300 times last year's earnings and roughly 210 times sales ^[5], after an IPO already priced at an aggressive 219 times earnings that the market then multiplied by six ^[10]. Its market value is about 1.4 times the entire $37 billion global humanoid market BofA Global Research projected for 2030 in an April report ^[15][16]. Measured against units actually delivered, the close works out to roughly $2.9 million per robot shipped ^[18].

The incentives around that number deserve naming. Only about 10% of the company was floated, raising 6.1 billion yuan, or $904 million ^[7], and the retail tranche was oversubscribed more than 5,500 times, with 9.8 million accounts chasing 9.7 million shares for an allocation rate of 0.018% ^[9]. That is a scarcity mechanic, not a demand curve for robots. Most U.S. investors cannot buy the shares directly; exposure runs through vehicles such as the KraneShares Humanoid Robotics and Physical AI ETF or its STAR Market 50 fund, with Unitree likely qualifying for STAR 50 inclusion around December if it holds enough of the gains ^[11].

The comparison exposes the gap. Agility Robotics agreed in June to go public via Churchill Capital Corp XI at a $2.5 billion pre-money valuation, netting about $620 million and trading as AGLT ^[19], with the SPAC's run to roughly $15.65 to $17 implying a value near $4 billion ^[20]. Agility has more than $300 million in committed multi-year orders for Digit v5 and deployments at Schaeffler, GXO, Toyota Motor Manufacturing Canada and Mercado Libre across nine facilities ^[21], though it is unprofitable and has not released revenue ^[22]. The firm with named industrial customers is worth roughly a thirteenth of the one whose disclosed near-term use is R&D and stage shows ^[24].

The consequence for operators is narrow and practical: any comp sheet citing Unitree is citing a 10% float in a quota-gated market, not a price for delivered industrial capability. Two things also sit outside the multiple. The Trump administration announced in July a ban on imports of new Chinese humanoids and quadruped robot dogs, and Unitree, which drew over 10% of sales from the U.S. last year, says the ban spares existing products but that newer models need U.S. government approval ^[27].